Literature DB >> 15980348

Novel approach to mapping of resistance mutations in whole genomes by using restriction enzyme modulation of transformation efficiency.

Claude G Lerner1, Stephan J Kakavas, Christian Wagner, Richard T Chang, Philip J Merta, Xiaoan Ruan, Randy E Metzger, Bruce A Beutel.   

Abstract

Restriction enzyme modulation of transformation efficiencies (REMOTE) is a method that makes use of genome restriction maps and experimentally observed differences in transformation efficiencies of genomic DNA restriction digests to discover the location of mutations in genomes. The frequency with which digested genomic DNA from a resistant strain transforms a susceptible strain to resistance is primarily determined by the size of the fragment containing the resistance mutation and the distance of the mutation to the end of the fragment. The positions of restriction enzyme cleavage sites immediately flanking the resistance mutation define these parameters. The mapping procedure involves a process of elimination in which digests that transform with high frequency indicate that the restriction enzyme cleavage sites are relatively far away from the mutation, while digests that transform with low frequency indicate that the sites are close to the mutation. The transformation data are compared computationally to the genome restriction map to identify the regions that best fit the data. Transformations with PCR amplicons encompassing candidate regions identify the resistance locus and enable identification of the mutation. REMOTE was developed using Haemophilus influenzae strains with mutations in gyrA, gyrB, and rpsE that confer resistance to ciprofloxacin, novobiocin, and spectinomycin, respectively. We applied REMOTE to identify mutations that confer resistance to two novel antibacterial compounds. The resistance mutations were found in genes that can decrease the intracellular concentration of compounds: acrB, which encodes a subunit of the AcrAB-TolC efflux pump; and fadL, which encodes a long-chain fatty acid transporter.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980348      PMCID: PMC1168657          DOI: 10.1128/AAC.49.7.2767-2777.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  54 in total

1.  PCR ligation mutagenesis in transformable streptococci: application and efficiency.

Authors:  Peter C Y Lau; Chang Kyoo Sung; Janet H Lee; Donald A Morrison; Dennis G Cvitkovitch
Journal:  J Microbiol Methods       Date:  2002-04       Impact factor: 2.363

Review 2.  Technologies for individual genotyping: detection of genetic polymorphisms in drug targets and disease genes.

Authors:  Michael M Shi
Journal:  Am J Pharmacogenomics       Date:  2002

Review 3.  Why is big Pharma getting out of antibacterial drug discovery?

Authors:  Steven J Projan
Journal:  Curr Opin Microbiol       Date:  2003-10       Impact factor: 7.934

Review 4.  Multi-resistant Gram-negative bacilli: from epidemics to endemics.

Authors:  Rafael Cantón; Teresa M Coque; Fernando Baquero
Journal:  Curr Opin Infect Dis       Date:  2003-08       Impact factor: 4.915

5.  Insertion-duplication mutagenesis in Streptococcus pneumoniae: targeting fragment length is a critical parameter in use as a random insertion tool.

Authors:  M S Lee; C Seok; D A Morrison
Journal:  Appl Environ Microbiol       Date:  1998-12       Impact factor: 4.792

6.  Mutation detection with MutH, MutL, and MutS mismatch repair proteins.

Authors:  J Smith; P Modrich
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

7.  Relation between the transforming activity of a marker and its proximity to the end of the DNA particle.

Authors:  H Lataste; J P Claverys; A M Sicard
Journal:  Mol Gen Genet       Date:  1981

8.  A strategy for discovery of novel broad-spectrum antibacterials using a high-throughput Streptococcus pneumoniae transcription/translation screen.

Authors:  Steven D Pratt; Caroline A David; Candace Black-Schaefer; Peter J Dandliker; Xiaoling Xuei; Usha Warrior; David J Burns; Ping Zhong; Zhensheng Cao; Anne Y C Saiki; Claude G Lerner; Linda E Chovan; Niru B Soni; Angela M Nilius; Frank L Wagenaar; Philip J Merta; Linda M Traphagen; Bruce A Beutel
Journal:  J Biomol Screen       Date:  2004-02

Review 9.  Fluoroquinolones: structure and target sites.

Authors:  P G Higgins; A C Fluit; F J Schmitz
Journal:  Curr Drug Targets       Date:  2003-02       Impact factor: 3.465

10.  Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes.

Authors:  Daniel R Gentry; Karen A Ingraham; Michael J Stanhope; Stephen Rittenhouse; Richard L Jarvest; Peter J O'Hanlon; James R Brown; David J Holmes
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

View more
  4 in total

1.  Differentially expressed outer membrane proteins of Vibrio alginolyticus in response to six types of antibiotics.

Authors:  Xiao-Peng Xiong; Chao Wang; Ming-Zhi Ye; Tian-Ci Yang; Xuan-Xian Peng; Hui Li
Journal:  Mar Biotechnol (NY)       Date:  2010-03-09       Impact factor: 3.619

2.  Clicking on trans-translation drug targets.

Authors:  John N Alumasa; Kenneth C Keiler
Journal:  Front Microbiol       Date:  2015-05-19       Impact factor: 5.640

3.  Characterization of nontypable Haemophilus influenzae isolates recovered from adult patients with underlying chronic lung disease reveals genotypic and phenotypic traits associated with persistent infection.

Authors:  Junkal Garmendia; Cristina Viadas; Laura Calatayud; Joshua Chang Mell; Pau Martí-Lliteras; Begoña Euba; Enrique Llobet; Carmen Gil; José Antonio Bengoechea; Rosemary J Redfield; Josefina Liñares
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

4.  Comparison of Proteomic Responses as Global Approach to Antibiotic Mechanism of Action Elucidation.

Authors:  Christoph H R Senges; Jennifer J Stepanek; Michaela Wenzel; Nadja Raatschen; Ümran Ay; Yvonne Märtens; Pascal Prochnow; Melissa Vázquez Hernández; Abdulkadir Yayci; Britta Schubert; Niklas B M Janzing; Helen L Warmuth; Martin Kozik; Jens Bongard; John N Alumasa; Bauke Albada; Maya Penkova; Tadeja Lukežič; Nohemy A Sorto; Nicole Lorenz; Reece G Miller; Bingyao Zhu; Martin Benda; Jörg Stülke; Sina Schäkermann; Lars I Leichert; Kathi Scheinpflug; Heike Brötz-Oesterhelt; Christian Hertweck; Jared T Shaw; Hrvoje Petković; Jean M Brunel; Kenneth C Keiler; Nils Metzler-Nolte; Julia E Bandow
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.